Why the study?
Does activated protein C alone or in combination with tissue plasminogen activator improve functional outcome and reduce brain infarction in rodents with embolic stroke?
Does activated protein C alone or in combination with tissue plasminogen activator improve functional outcome and reduce brain infarction in rodents with embolic stroke?
Activated protein C shows promise as a neuroprotective therapy that may improve outcomes and extend the time window for thrombolytic therapy in stroke.
May extend thrombolytic window in rodent stroke models; leaves open human translation and safety.
A serine protease activated protein C has been shown to be a powerful neuroprotectant in stressed neurons and in hypoxic brain endothelium. In a clinically relevant model of embolic stroke in rodents, we now show that administration of activated protein C alone or in combination with tissue plasminogen activator, or both, 4 hours after embolic stroke improves the functional outcome and reduces brain infarction within 7 days of stroke. In contrast, tissue plasminogen activator alone was not protective. Thus, activated protein C may be useful as a new stand-alone therapy for clinical stroke and to extend the time window of thrombolytic therapy.
No takes yet. Share an insight, caveat, or question.
Zloković et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: